These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22056744)

  • 21. Identification and characterization of a new reversible MAGL inhibitor.
    Tuccinardi T; Granchi C; Rizzolio F; Caligiuri I; Battistello V; Toffoli G; Minutolo F; Macchia M; Martinelli A
    Bioorg Med Chem; 2014 Jul; 22(13):3285-91. PubMed ID: 24853323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase.
    Feledziak M; Michaux C; Urbach A; Labar G; Muccioli GG; Lambert DM; Marchand-Brynaert J
    J Med Chem; 2009 Nov; 52(22):7054-68. PubMed ID: 19877691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationship of a new series of reversible dual monoacylglycerol lipase/fatty acid amide hydrolase inhibitors.
    Cisneros JA; Björklund E; González-Gil I; Hu Y; Canales A; Medrano FJ; Romero A; Ortega-Gutiérrez S; Fowler CJ; López-Rodríguez ML
    J Med Chem; 2012 Jan; 55(2):824-36. PubMed ID: 22185522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors.
    Aida J; Fushimi M; Kusumoto T; Sugiyama H; Arimura N; Ikeda S; Sasaki M; Sogabe S; Aoyama K; Koike T
    J Med Chem; 2018 Oct; 61(20):9205-9217. PubMed ID: 30251836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay.
    Muccioli GG; Labar G; Lambert DM
    Chembiochem; 2008 Nov; 9(16):2704-10. PubMed ID: 18855964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Optimization of 4-Chlorobenzoylpiperidine Derivatives for the Development of Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors.
    Granchi C; Rizzolio F; Palazzolo S; Carmignani S; Macchia M; Saccomanni G; Manera C; Martinelli A; Minutolo F; Tuccinardi T
    J Med Chem; 2016 Nov; 59(22):10299-10314. PubMed ID: 27809504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel reversible monoacylglycerol lipase inhibitors via docking-based virtual screening.
    Xiong F; Ding X; Zhang H; Luo X; Chen K; Jiang H; Luo C; Xu H
    Bioorg Med Chem Lett; 2021 Jun; 41():127986. PubMed ID: 33766770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loratadine analogues as MAGL inhibitors.
    Patel JZ; Ahenkorah S; Vaara M; Staszewski M; Adams Y; Laitinen T; Navia-Paldanius D; Parkkari T; Savinainen JR; Walczyński K; Laitinen JT; Nevalainen TJ
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1436-42. PubMed ID: 25752982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The medicinal chemistry of agents targeting monoacylglycerol lipase.
    Viso A; Cisneros JA; Ortega-Gutiérrez S
    Curr Top Med Chem; 2008; 8(3):231-46. PubMed ID: 18289090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis.
    Hernández-Torres G; Cipriano M; Hedén E; Björklund E; Canales Á; Zian D; Feliú A; Mecha M; Guaza C; Fowler CJ; Ortega-Gutiérrez S; López-Rodríguez ML
    Angew Chem Int Ed Engl; 2014 Dec; 53(50):13765-70. PubMed ID: 25298214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Monoacylglycerol Lipase in Pursuit of Therapies for Neurological and Neurodegenerative Diseases.
    Zanfirescu A; Ungurianu A; Mihai DP; Radulescu D; Nitulescu GM
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study.
    Jha V; Biagi M; Spinelli V; Di Stefano M; Macchia M; Minutolo F; Granchi C; Poli G; Tuccinardi T
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33375358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors.
    Granchi C; Rizzolio F; Bordoni V; Caligiuri I; Manera C; Macchia M; Minutolo F; Martinelli A; Giordano A; Tuccinardi T
    J Enzyme Inhib Med Chem; 2016; 31(1):137-46. PubMed ID: 25669350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system.
    Chanda PK; Gao Y; Mark L; Btesh J; Strassle BW; Lu P; Piesla MJ; Zhang MY; Bingham B; Uveges A; Kowal D; Garbe D; Kouranova EV; Ring RH; Bates B; Pangalos MN; Kennedy JD; Whiteside GT; Samad TA
    Mol Pharmacol; 2010 Dec; 78(6):996-1003. PubMed ID: 20855465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-Activity Relationship Studies of Aryl Sulfoxides as Reversible Monoacylglycerol Lipase Inhibitors.
    Jiang M; Huizenga MCW; Mohr F; Amedi A; Bakker R; van den Berg RJBHN; Deng H; van der Wel T; van Boeckel CAA; van der Stelt M
    J Med Chem; 2024 Jul; 67(14):12331-12348. PubMed ID: 38988250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
    Granchi C; Lapillo M; Glasmacher S; Bononi G; Licari C; Poli G; El Boustani M; Caligiuri I; Rizzolio F; Gertsch J; Macchia M; Minutolo F; Tuccinardi T; Chicca A
    J Med Chem; 2019 Feb; 62(4):1932-1958. PubMed ID: 30715876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an HPLC/UV assay for the evaluation of inhibitors of human recombinant monoacylglycerol lipase.
    Del Carlo S; Manera C; Chicca A; Arena C; Bertini S; Burgalassi S; Tampucci S; Gertsch J; Macchia M; Saccomanni G
    J Pharm Biomed Anal; 2015 Apr; 108():113-21. PubMed ID: 25743577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors.
    Granchi C; Caligiuri I; Bertelli E; Poli G; Rizzolio F; Macchia M; Martinelli A; Minutolo F; Tuccinardi T
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):1240-1252. PubMed ID: 28936880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2
    Ikeda S; Sugiyama H; Tokuhara H; Murakami M; Nakamura M; Oguro Y; Aida J; Morishita N; Sogabe S; Dougan DR; Gay SC; Qin L; Arimura N; Takahashi Y; Sasaki M; Kamada Y; Aoyama K; Kimoto K; Kamata M
    J Med Chem; 2021 Aug; 64(15):11014-11044. PubMed ID: 34328319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors.
    Aghazadeh Tabrizi M; Baraldi PG; Baraldi S; Ruggiero E; De Stefano L; Rizzolio F; Di Cesare Mannelli L; Ghelardini C; Chicca A; Lapillo M; Gertsch J; Manera C; Macchia M; Martinelli A; Granchi C; Minutolo F; Tuccinardi T
    J Med Chem; 2018 Feb; 61(3):1340-1354. PubMed ID: 29309142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.